# Medical Oncology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Edward W. Brooke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML014-SYN
- Date: 2026-01-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Howard Bellamy, MD
- Calendar frame: modern shifted

- To: Mei-Ling Cho, MD, Medical Oncology
- Urgency: Routine, within four weeks

## Referral question

Man of 83 with stage IIA, hormone receptor-positive, HER2-negative right breast cancer, fourteen weeks after bilateral mastectomy and right axillary dissection, on tamoxifen for eleven weeks, started at another hospital. Please take over his adjuvant endocrine therapy, confirm the adjuvant plan, and arrange germline genetic testing. **S**

## Questions for the consultant

1. Is tamoxifen the right adjuvant endocrine therapy for him, and for how long?
2. Is any other adjuvant treatment, such as chemotherapy or radiation, indicated now?
3. Which germline test should he have, and what would a result mean for him and his relatives?
4. How should tamoxifen safety be monitored at his age, and which medicines should he avoid?
5. What surveillance does he need after bilateral mastectomy, and what should be done about his bone health?

## Pertinent history

He noticed discomfort in the right breast and at first put it down to aging or a strained muscle; he had never had a chest examination by a doctor. Mammography and ultrasound of both breasts showed a 1.9 cm right retroareolar mass and an abnormal right axillary node; the left breast and axilla were normal. Core biopsy: invasive ductal carcinoma, grade 2, ER 95 percent, PR 80 percent, HER2 1+, Ki-67 15 percent, with a positive node. Bilateral mastectomy and right axillary dissection: 1.8 cm tumor, margins clear, 1 of 14 nodes involved (4 mm, no extranodal extension), pT1c pN1a. No chemotherapy or radiation was given. Tamoxifen 20 mg daily since four weeks after surgery, with mild hot flashes. No germline testing yet. No history of blood clots, stroke, or liver disease. Never smoker; no alcohol. Hemoglobin 13.8 g/dL, platelets 214, eGFR 71, liver tests normal, 25-hydroxyvitamin D 24 ng/mL. PHQ-9 score 3. DXA booked. No family history is recorded. **S**

- Edward William Brooke III was born in Washington, D.C., on October 26, 1919. **D**
- Brooke was elected attorney general of Massachusetts in 1962 and re-elected in 1964, and in 1966 became the first African American elected to the U.S. Senate by popular vote; he served as a Republican senator from Massachusetts from January 3, 1967, to January 3, 1979. **D**
- In a CNN interview aired on June 11, 2003, Brooke said that in September 2002 he felt discomfort in his right breast, which he dismissed as aging, possible muscle strain, or gas; that he then had a mammogram, a sonogram, and a needle biopsy, which found a malignant tumor; that his breasts had never before been examined by a doctor; and that he had not thought men got breast cancer. **D**
- In the same interview Brooke said he had to be operated on for breast cancer, that the cancer had spread to his lymph nodes, and that all of the lymph nodes on his right side were removed. **D**
- An Associated Press report of June 11, 2003, said that Brooke, 83, had been diagnosed with breast cancer in September, had a double mastectomy, and was free of the cancer, and that he was encouraging men to examine themselves and urging insurers to cover mammograms for men. **D**
- In the 2003 interview Brooke described himself as not a smoker or a drinker and said he exercised and ate fairly good food. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin: 13.8 g/dL; White cell count: 6.1 10*3/uL; Platelets: 214 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.04 mg/dL; eGFR: 71 mL/min/1.73 m²; Calcium: 9.3 mg/dL; ALT: 19 U/L; AST: 23 U/L; Alkaline phosphatase: 76 U/L; Total bilirubin: 0.6 mg/dL; Albumin: 4 g/dL; 25-hydroxyvitamin D: 24 ng/mL (low); PHQ-9: 3. All results are synthetic.

BP 134/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 81.6 kg; BMI 24.4 kg/m². All vital signs are synthetic.

## Current medications

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) **S**

## Plan so far

- Tamoxifen 20 mg daily for an initial five years, with venous thromboembolism symptoms, mood, hot flashes, sexual side effects, adherence, and interacting medicines reviewed at every visit. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), with a letter for first-degree relatives explaining the result. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024) **S**
- Bone health: DXA at baseline, vitamin D repletion, dietary calcium, and weight-bearing exercise; bone-modifying drugs only for osteoporosis, not to prevent recurrence. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Survivorship surveillance: cancer-related history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly; no routine imaging, blood tests, or tumor markers without symptoms; lymphedema checks. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Distress screening at each visit, at least 150 minutes of activity a week, and a written survivorship care plan. Guideline: Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
